MDX-1097: Phase I started

Immune System (formerly PacMab Ltd.) began an open-label, single ascending-dose, Australian Phase I trial to evaluate 0.3, 1.0, 3.0, 10 or 30 mg/kg of intravenous MDX-1097 in 15 patients. The company...